Roquette completes acquisition of IFF Pharma Solutions

Image | adobe.stock/Natee Meepian

Roquette has completed its acquisition of IFF Pharma Solutions. This acquisition follows the 2023 acquisition of Qualicaps from Mitsubishi Chemical Group. The integration of IFF Pharma Solution’s expertise and innovative product portfolio enhances Roquette’s “ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide while reinforcing its commitment to innovation,” according to the company’s press release.

“The successful acquisition of IFF Pharma Solutions marks a major step forward in our value-creation journey,” said Pierre Courduroux, CEO of Roquette, in a press release. “We are thrilled to officially welcome our new colleagues as we start to write the next chapter of Roquette's history. This pivotal move aligns perfectly with our strategic vision to provide innovative, high-quality excipients that improve the efficacy and safety of pharmaceutical formulations. By combining our strengths, Roquette is poised to become the pharmaceutical industry’s go-to partner for the development of drug delivery solutions that contribute to improving, sustaining, and saving patients’ lives.”

The acquisition was originally announced in March of 2024. “We are pleased to reach an agreement with Roquette that will support Pharma Solutions’ next chapter of growth as a trusted partner for the pharmaceutical industry,” said Erik Fyrwald, CEO of IFF, in a press release. “This represents a great opportunity for our team and customers. Roquette is the ideal strategic partner for IFF Pharma Solutions, with whom it has complementary portfolio and innovation capabilities, and with whom it shares a culture of operational excellence.”